…
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company developing T-cell therapies for solid tumors and hematologic malignancies. Growth drivers include clinical trial progress, regulatory approvals, manufacturing scale-up and partnerships that could support adoption of personalized cell therapies. Investors may view the company as exposure to differentiated cell therapy approaches in a large oncology market.
Key risks are clinical or regulatory setbacks, high capital and manufacturing needs, strong competition from larger oncology firms, and shareholder dilution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -12.18M | -10.68M | -14.04M | -29.93M | -41.88M |
| Net income | -12.16M | -10.73M | -8.24M | -29.92M | -41.87M |
| Selling general administrative | 4.18M | 4.24M | 7.48M | 12.82M | 12.92M |
| Gross profit | - | -6.88M | -7.11M | 9.00M | 1.24M |
| Reconciled depreciation | - | - | - | 3.68M | 3.16M |
| Ebit | - | -10.68M | -14.04M | -29.95M | -39.48M |
| Ebitda | -12.44M | -10.68M | -11.25M | -26.27M | -36.32M |
| Depreciation and amortization | - | 0.00M | 2.79M | 3.68M | 3.16M |
| Operating income | -12.89M | -11.12M | -14.58M | -29.95M | -39.48M |
| Other operating expenses | 12.89M | 17.71M | 17.89M | 38.96M | 40.72M |
| Interest expense | - | - | - | -0.02M | 0.01M |
| Tax provision | -0.02M | 0.05M | 0.00M | - | - |
| Interest income | 0.59M | 0.44M | 0.45M | 0.25M | 0.01M |
| Net interest income | 0.59M | 0.44M | 0.45M | 0.25M | 0.01M |
| Income tax expense | -0.02M | 0.05M | 0.00M | -0.02M | -0.01M |
| Total revenue | 3.55M | 6.59M | 3.31M | 9.00M | 1.24M |
| Total operating expenses | 12.89M | 4.24M | 7.48M | 38.96M | 40.72M |
| Cost of revenue | - | 13.47M | 10.42M | - | - |
| Total other income expense net | 0.71M | 0.44M | 0.54M | 0.02M | -2.40M |
| Net income from continuing ops | -12.16M | -10.73M | -24.50M | -29.93M | -41.88M |
| Net income applicable to common shares | - | - | - | - | -41.88M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19.07M | 22.02M | 17.13M | 34.42M | 68.14M |
| Other current assets | 1.63M | 0.48M | 0.99M | 2.44M | 3.63M |
| Total liab | 2.27M | 3.46M | 3.07M | 14.82M | 24.15M |
| Total stockholder equity | 16.80M | 18.56M | 14.05M | 19.60M | 43.99M |
| Other current liab | 0.51M | 2.29M | 2.11M | 3.09M | 5.99M |
| Common stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.08M |
| Capital stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.08M |
| Retained earnings | -459.18M | -447.02M | -436.29M | -428.05M | -398.12M |
| Other assets | - | - | - | - | -0.00M |
| Cash | 16.07M | 19.19M | 15.11M | 11.78M | 42.35M |
| Total current liabilities | 2.27M | 3.46M | 3.07M | 7.78M | 12.90M |
| Current deferred revenue | 0.97M | - | - | 2.50M | 1.15M |
| Net debt | -16.07M | -19.19M | -15.11M | -4.17M | -30.48M |
| Short term debt | - | - | - | 0.58M | 0.62M |
| Short long term debt total | - | - | - | 7.62M | 11.87M |
| Other stockholder equity | 475.96M | 465.56M | 450.33M | 447.64M | 442.02M |
| Property plant equipment | - | - | - | - | 22.15M |
| Total current assets | 19.07M | 22.02M | 17.13M | 16.62M | 45.98M |
| Net tangible assets | - | - | - | - | 43.99M |
| Short term investments | - | 19192420.81M | - | - | - |
| Net receivables | 1.37M | 2.35M | 1.03M | 2.40M | 0.00M |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 0.79M | 1.07M | 0.96M | 1.61M | 5.14M |
| Non currrent assets other | - | - | - | - | 2.23M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 17.80M | 22.15M |
| Capital lease obligations | - | - | - | 7.62M | 11.87M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 18.54M | -4.95M | -3.13M |
| Change to liabilities | - | - | - | - | 5.29M |
| Total cashflows from investing activities | - | - | 18.66M | - | -3.13M |
| Total cash from financing activities | 9.86M | 14.99M | 1.11M | 0.20M | 52.56M |
| Change to operating activities | - | - | - | - | -0.82M |
| Net income | -12.16M | -10.73M | -14.05M | -29.93M | -41.88M |
| Change in cash | -2.15M | 4.08M | 3.33M | -31.72M | 22.14M |
| Begin period cash flow | 19.19M | 15.11M | 11.78M | 43.50M | 21.35M |
| End period cash flow | 17.04M | 19.19M | 15.11M | 11.78M | 43.50M |
| Total cash from operating activities | -12.01M | -10.91M | -16.44M | -26.97M | -27.28M |
| Issuance of capital stock | 9.86M | 14.93M | 1.15M | 0.20M | 52.55M |
| Depreciation | - | - | - | 3.68M | 3.16M |
| Other cashflows from investing activities | - | - | 18.66M | - | - |
| Change to account receivables | 0.98M | -1.32M | 1.37M | - | 1.00M |
| Other cashflows from financing activities | 9864478.14M | 0.06M | 0.09M | -4.95M | 0.00M |
| Change to netincome | - | - | - | - | 5.96M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 4.95M | 3.13M |
| Change in working capital | -0.39M | -0.42M | 2.85M | -5.81M | 5.47M |
| Stock based compensation | 0.54M | 0.25M | 0.86M | 5.34M | 5.96M |
| Other non cash items | -388000.61M | -11156176.84M | -6.10M | -0.25M | 0.00M |
| Free cash flow | -12.01M | -10.91M | -16.44M | -31.92M | -30.41M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MRKR Marker Therapeutics Inc |
-0.03 3.33% |
0.87 | - | - | 5.50 | 1.60 | 0.72 | -0.22 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter L. Hoang MBA | Pres, CEO & Director | 1972 |
| Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer | 1978 |
| Dr. Juan F. Vera M.D. | Co-Founder, COO, Chief Scientific Officer & Director | 1980 |
| Mr. Michael J. Loiacono | Chief Accounting Officer, Treasurer & Sec. | 1966 |
| Ms. Elizabeth Donnelly | Director of Admin. | NA |
| Mr. Edmund Cheung | VP of HR | NA |
| Dr. Nadia Agopyan Ph.D. | Sr. VP of Regulatory Affairs | NA |
| Dr. Robert Z. Florkiewicz Sr. | Sr. Director of Molecular Biology & Virology | NA |
| Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer & Director | 1981 |
| Ms. Elizabeth Donnelly | Director of Administration | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.